Golara Honari, MD

All Publications

• Letter: Disparities in Patch Testing for Allergic Contact Dermatitis: Insights From a National Electronic Health Record Dataset. Dermatitis : contact, atopic, occupational, drug Shah, M. M., Chen, J. K., Honari, G. 2026: 17103568261451685

  View details for DOI 10.1177/17103568261451685

  View details for PubMedID 42157623

• Clinical Spectrum of Hypersensitivity and Granulomatous Reactions to VenaSeal™ Cyanoacrylate Closure. Dermatitis : contact, atopic, occupational, drug Shah, M. M., Fukaya, E., Honari, G., Chen, J. K., Bae, G. H. 2026: 17103568261446233

  Abstract

  The VenaSeal™ Closure System uses n-butyl-2-cyanoacrylate for minimally invasive treatment of chronic venous disease. While generally safe, reported adverse events include phlebitis, hypersensitivity, foreign body granulomas, and endovenous glue-induced thrombosis. Specifically, hypersensitivity reactions have been reported in 6.3%-13% of patients.We present 4 patients with heterogeneous cutaneous and systemic reactions following CAC, ranging from localized nodules to erythroderma. Diagnostic evaluation included patch testing, ultrasound, CT, and histopathology, with varying findings for each case.Consequently, treatments ranged from intralesional corticosteroids to prolonged systemic corticosteroids and surgical excision.This case series highlights the limitations of patch testing, the importance of considering imaging and biopsy for diagnosis, and the need for individualized management strategies.

  View details for DOI 10.1177/17103568261446233

  View details for PubMedID 42077140

• Facial Rash Events in Dupilumab Phase 3 Atopic Dermatitis Trials: A Pooled Analysis. Dermatitis : contact, atopic, occupational, drug Paller, A. S., de Bruin-Weller, M., Simpson, E. L., Ahn, J., Chovatiya, R., Deleuran, M., Honari, G., Gherardi, G., Coleman, A., Lawless, E., Chen, Z., Shumel, B., Rossi, A. B. 2025

  Abstract

  Background: Since dupilumab approval for moderate-to-severe atopic dermatitis (AD) in 2017, facial rash reports appeared in literature. Objective: To report facial rash treatment-emergent adverse events (TEAEs) incidence in dupilumab clinical trials for moderate-to-severe AD. Methods: Data were pooled from 14 randomized, placebo-controlled dupilumab clinical trials in pediatric (6-17 years) and adult (≥18 years) patients and were searched for facial rash TEAEs occurring during study treatment period, focusing on Medical Dictionary for Regulatory Activities (MedDRA) Lowest Level Terms (LLTs). Results: Pooled dataset included 1349 placebo-treated and 2615 dupilumab-treated patients. Facial rash incidence was low but slightly higher in dupilumab (dupilumab: 25 [1.0%]; placebo: 9 [0.7%] patients). The following LLT rates were numerically higher in dupilumab than placebo-treated patients: Erythema facial (7 [0.3%, 0.8 number of events (nE)/100 patient-years (PY)] vs 1 [<0.1%, 0.1 nE/100PY]); Redness facial (2 [<0.1%, 0.2 nE/100PY] vs 0); and rash on face (5 [0.2%, 0.4 nE/100PY] vs 1 [<0.1%, 0.1 nE/100PY]). Most cases were mild-to-moderate and recovered/resolved during study period; none led to treatment discontinuation. Conclusions: Facial rash analysis focused on MedDRA LLTs in dupilumab clinical trials for moderate-to-severe AD showed a small increase in dupilumab-treated patients compared with placebo. Most were mild-to-moderate and not treatment-limiting.

  View details for DOI 10.1177/17103568251386871

  View details for PubMedID 41163262

• An Evaluation of Potential Allergens in over-the-Counter Nasal Products. Dermatitis : contact, atopic, occupational, drug Rezaei, S. J., Honari, G., Chen, J. K. 2025

  View details for DOI 10.1089/derm.2025.0018

  View details for PubMedID 40049626

• Barriers to Health Care Affordability Among Parents of Children with Atopic Dermatitis. Dermatitis : contact, atopic, occupational, drug Youn, C. G., Bae, G. H., Honari, G., Chen, J. K., Sarin, K. Y., Siegel, D. H. 2025

  Abstract

  Abstracts: Background: Pediatric atopic dermatitis (AD) can pose a significant financial burden to families. However, no studies exist that assess the impact of pediatric AD on health care access/affordability at the parental level. Objective: Explore the effects of childhood AD on parental access to health care and the socioeconomic factors that might exacerbate these problems. Methods: The National Health Interview Survey was used to analyze 48,329,314 participants who answered the validated question on pediatric AD. Multivariable logistic regression analyses were performed to assess the association between pediatric AD and parental access to care. Results: Parents of children with AD were more likely to have difficulty accessing prescription medications (aOR: 1.47; [95% CI 1.31-1.65]), follow-up care (1.36; [95% CI 1.17-1.57]), specialist care (aOR: 1.53; [95% CI 1.33-1.75]), and more likely to purchase medications from abroad (aOR: 1.35; [95% CI 1.09-1.67]) relative to their counterparts with children without AD. Within the AD cohort, uninsured or lower income participants had higher odds of facing these barriers to care. Conclusions: Parents of children with AD are more likely to face barriers in health care access, and significant disparities exist based on sociodemographic characteristics.

  View details for DOI 10.1089/derm.2024.0248

  View details for PubMedID 39937150

• Prevalence of Potential Allergens in Commonly Available Over-the-Counter Ear Care Products. Dermatitis : contact, atopic, occupational, drug Rezaei, S. J., Honari, G., Chen, J. K. 2024

  View details for DOI 10.1089/derm.2024.0134

  View details for PubMedID 39403739

• Efficacy of dupilumab treatment in atopic hand and foot dermatitis across morphological subtypes and patch test: Results from a phase 3, randomized, double-blind, placebo-controlled study Worm, M., Simpson, E. L., Petrova, A., Honari, G., Soong, W., Pinter, A., Masuda, K., Chen, Z., Dubost-Brama, A., Bansal, A., Korotzer, A., Rossi, A. B. WILEY. 2024: 804

  View details for Web of Science ID 001365907700054

• The Skin and Lewy Body Disease. Journal of Alzheimer's disease : JAD Cassard, L., Honari, G., Tousi, B. 2024

  Abstract

  This manuscript reviews the significant skin manifestations of Lewy body disease, including Parkinson's disease and dementia with Lewy bodies, and the diagnostic utility of skin biopsy. Besides classic motor and cognitive symptoms, non-motor manifestations, particularly dermatologic disorders, can play a crucial role in disease presentation and diagnosis. This review explores the intricate relationship between the skin and Lewy body disease. Seborrheic dermatitis, autoimmune blistering diseases (bullous pemphigoid and pemphigus), rosacea, and melanoma are scrutinized for their unique associations with Parkinson's disease, revealing potential links through shared pathophysiological mechanisms. Advances in diagnostic techniques allow the identification of promising biomarkers such as α-synuclein in samples obtained by skin punch biopsy. Understanding the dermatologic aspects of Lewy body disease not only contributes to its holistic characterization but also holds implications for innovative diagnostic approaches.

  View details for DOI 10.3233/JAD-240198

  View details for PubMedID 38968048

• Parental E-Cigarette Use and Pediatric Atopic Dermatitis. JAMA dermatology Youn, G. M., Sarin, K. Y., Chiou, A. S., Chen, J. K., Honari, G. 2024

  Abstract

  This cross-sectional study uses data from the 2014-2018 National Health Interview Survey to assess whether there is an association between parental e-cigarette use and atopic dermatitis in children.

  View details for DOI 10.1001/jamadermatol.2024.1283

  View details for PubMedID 38776098

• Efficacy of dupilumab treatment in atopic hand and foot dermatitis across morphological subtypes: results from a phase 3, randomized, double-blind, placebo-controlled trial Worm, M., Simpson, E. L., Honari, G., Soong, W., Pinter, A., Masuda, K., Shao, L., Dubost-Brama, A., Bansal, A., Korotzer, A., Rossi, A. B. OXFORD UNIV PRESS. 2024: II60

  View details for DOI 10.1093/bjd/ljad498.062

  View details for Web of Science ID 001158354000064

• Dupilumab treatment improves signs, symptoms, quality of life and work productivity in patients with atopic hand and foot dermatitis: results from a phase 3, randomized, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology Simpson, E. L., Silverberg, J. I., Worm, M., Honari, G., Masuda, K., Sygula, E., Schuttelaar, M. L., Mortensen, E., Laws, E., Akinlade, B., Patel, N., Maloney, J., Paleczny, H., Delevry, D., Xiao, J., Dubost-Brama, A., Bansal, A. 2024

  Abstract

  Despite high disease burden, systemic treatment options for patients with atopic hand and/or foot dermatitis (H/F AD) are limited.To evaluate efficacy and safety of dupilumab in H/F AD using specific instruments for assessing disease severity on hands and feet.In this multicenter phase 3 trial, adults and adolescents with moderate-to-severe H/F AD were randomized to dupilumab monotherapy (regimen approved for generalized AD), or matched placebo. The primary endpoint was proportion of patients achieving Hand and Foot Investigator's Global Assessment (HF-IGA) score 0 or 1 at week 16. Secondary pre-specified endpoints assessed the severity and extent of signs, symptom intensity (itch, pain), quality of life, and sleep.133 patients (adults=106, adolescents=27) were randomized to dupilumab (n=67) or placebo (n=66). At week 16, significantly more patients receiving dupilumab (n=27) than placebo (n=11) achieved HF-IGA score 0 or 1 (40.3% vs 16.7%; P=.003). All other pre-specified endpoints were met. Safety was consistent with the known AD dupilumab profile.Short-term, 16-week treatment period.Dupilumab monotherapy resulted in significant improvements across different domains of H/F AD with acceptable safety, supporting dupilumab as a systemic treatment approach for this often difficult to treat condition.

  View details for DOI 10.1016/j.jaad.2023.12.066

  View details for PubMedID 38296199

• Dupilumab treatment in patients with atopic hand and foot dermatitis: results from a phase 3, randomized, double-blind, placebo-controlled trial Simpson, E. L., Silverberg, J., Worm, M., Honari, G., Masuda, K., Sygula, E., Maloney, J., Mannent, L. P., Xiao, J., Dubost-Brama, A., Bansal, A. OXFORD UNIV PRESS. 2023

  View details for DOI 10.1093/bjd/ljad162.029

  View details for Web of Science ID 001023047700060

• Prevalence of allergic contact dermatitis following patch testing in patients with atopic dermatitis: a retrospective United States claims-based study. Journal of the American Academy of Dermatology Qian, M. F., Li, S., Honari, G., Sarin, K. Y., Chen, J. K. 2023

  View details for DOI 10.1016/j.jaad.2022.12.051

  View details for PubMedID 36775101

• DUPILUMAB TREATMENT IN PATIENTS WITH ATOPIC HAND AND FOOT DERMATITIS: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL Simpson, E. L., Silverberg, J. I., Worm, M., Honari, G., Masuda, K., Schuttelaar, M. A., Maloney, J., Xiao, J., Dubost-Brama, A., Bansal, A. ACTA DERMATO-VENEREOLOGICA. 2023: 53-54

  View details for Web of Science ID 001101863700148

• Sociodemographic disparities in patch testing for commercially insured patients with dermatitis: A retrospective analysis of administrative claims data JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY Qian, M. F., Li, S., Honari, G., Sarin, K. Y., Chen, J. K. 2022; 87 (6): 1411-1413

  View details for DOI 10.1016/j.jaad.2022.08.042

  View details for Web of Science ID 000927902100013

• Association of Intraoperative Antibiotic Irrigation With Systemic Contact Dermatitis. JAMA dermatology So, J. Y., Suzuki, N., Chen, J. K., Pugliese, S., Kwong, B. Y., Meng, L., Honari, G. 2022

  Abstract

  This case series describes the development of morbilliform drug eruption after breast surgery.

  View details for DOI 10.1001/jamadermatol.2022.4458

  View details for PubMedID 36383358

• Assessment of Comorbidities Associated With Allergic Contact Dermatitis in the United States: A Retrospective Claims-Based Study. Dermatitis : contact, atopic, occupational, drug Hua, V. J., Li, S., Qian, M. F., Honari, G., Sarin, K. Y., Chen, J. K. 2022

  Abstract

  BACKGROUND: Allergic contact dermatitis (ACD) is a common dermatologic disease. Patch testing remains the criterion standard for diagnosis. In clinical practice, avoidance may be limited by patient occupation or noncompliance, the pervasive nature of the culprit agent, or barriers to expert care because of socioeconomic, cultural, or geographic factors. Thus, ACD is frequently chronic and/or recurrent; however, the comorbidities associated with ACD are not well characterized.OBJECTIVE: The aim of the study is to identify associations between ACD and psychiatric, sleep health, cardiovascular, and infectious conditions.METHODS: In this study, we used a large US claims database to identify comorbidities associated with ACD diagnosed after patch testing, including psychiatric, sleep health, cardiovascular, and infectious conditions. We also stratified these associations by chronicity of disease.RESULTS: We identified associations between ACD and psychiatric, sleep-related, cardiovascular, and infectious comorbidities. We also found that more chronic ACD was associated with more infectious comorbidities. All of these associations remained significant on further subanalysis when patients with AD and venous stasis were excluded.CONCLUSIONS: Allergic contact dermatitis is associated with multiple comorbidities. Further study is required to corroborate these findings, determine causality, and to explore the impact of possible interventions in the workup and management of this common and often debilitating disease.

  View details for DOI 10.1097/DER.0000000000000964

  View details for PubMedID 36255394

• Sociodemographic disparities in patch testing for commercially insured dermatitis patients: a retrospective analysis of administrative claims data. Journal of the American Academy of Dermatology Qian, M. F., Li, S., Honari, G., Sarin, K. Y., Chen, J. K. 2022

  View details for DOI 10.1016/j.jaad.2022.08.041

  View details for PubMedID 36041554

• Chronic Dermatitis Due to Jellyfish Envenomation. Dermatitis : contact, atopic, occupational, drug So, J. Y., Honari, G. 2022

  View details for DOI 10.1097/DER.0000000000000930

  View details for PubMedID 35943348

• Expert Opinion on Patch Testing While Receiving Immunomodulatory Therapy Results of an International Survey Study DERMATITIS Honari, G. 2022; 33 (4): E51-E53

  View details for DOI 10.1097/DER.0000000000000837

  View details for Web of Science ID 000825573500005

  View details for PubMedID 35089899

• Monographs in Contact Allergy: Topical Drugs by Anton de Groot, Bocca Raton, FL: CRC Press; 2021. ISBN: ISBN-13: 978-0367236939. Dermatitis : contact, atopic, occupational, drug Honari, G. 2022

  View details for DOI 10.1097/DER.0000000000000891

  View details for PubMedID 35674515

• Allergic Contact Dermatitis of the Scalp Associated With Scalp Applied Products: A Systematic Review of Topical Allergens. Dermatitis : contact, atopic, occupational, drug Pham, C. T., Juhasz, M., Lin, J., Hashemi, K., Honari, G., Mesinkovska, N. A. 2022

  Abstract

  ABSTRACT: Hair products are commonly used to maintain hair health or cosmesis. Products applied to the scalp and hair contain multiple active and inactive ingredients that can potentially cause irritant and/or allergic contact dermatitis. The objectives of this study were to identify and to discuss the most common allergens in scalp and hair applied products causing scalp allergic contact dermatitis (ACD). A PubMed search identified 99 studies, with 3185 patients and 31 categories of scalp products. Hair products reportedly associated with scalp ACD were hair dyes (41%), shampoos (28%), and conditioners (22%). The most commonly reported patch test-positive allergens were p-phenylenediamine (23%), nickel (15%), fragrance mix (13%), balsam of Peru (10%), cocamidopropyl betaine/3-dimethylaminopropylamine (7%), and methylchloroisothiazolinone/methylisothiazolinone (6%). Common symptoms and signs include eczematous lesions, pruritus, and a burning sensation. Medical practitioners should be aware of causative agents to provide appropriate patient education, counseling, and/or treatment.

  View details for DOI 10.1097/DER.0000000000000844

  View details for PubMedID 35318978

• Allergic contact dermatitis associated with scalp applied products: A systematic review of topical allergens and alopecia implication Pham, C., Juhasz, M., Lin, J., Honari, G., Mesinkovska, N. MOSBY-ELSEVIER. 2021: AB49

  View details for Web of Science ID 000683887500191

• Automated detection of skin reactions in epicutaneous patch testing using machine learning. The British journal of dermatology Chan, W. H., Srivastava, R., Damaraju, N., Do, H., Burnett, G., MacFarlane, J., Xie, S. M., Chen, J. K., Honari, G., Sarin, K. Y. 2021

  Abstract

  Patch testing is the diagnostic gold standard to identify causes of allergic contact dermatitis (ACD); however, the paucity of specialized patch testing clinics along with the need for multiple clinic visits can be burdensome for patients and healthcare systems. Automated classification of allergic reactions from photographs offers the opportunity to reduce patient, physician, and clinic time and improve access to care.

  View details for DOI 10.1111/bjd.20141

  View details for PubMedID 33829497

• Bridging to a selective Janus kinase 1 inhibitor in severe atopic dermatitis: An instructive case with upadacitinib. JAAD case reports Nguyen, J., Chen, J. K., Honari, G., Pol-Rodriguez, M., Ko, J. M., Chiou, A. S. 2021; 7: 65–67

  View details for DOI 10.1016/j.jdcr.2020.10.023

  View details for PubMedID 33354610

• Prevalence of Potentially Allergenic Ingredients in Products Labeled for Eczema Care. Journal of the American Academy of Dermatology Schwartz, B. L., Honari, G., Chiou, A. S., Ko, J., Sarin, K. Y., Chen, J. K. 2021

  View details for DOI 10.1016/j.jaad.2021.05.038

  View details for PubMedID 34058279

• Photopatch Testing Among Members of the American Contact Dermatitis Society. Dermatitis : contact, atopic, occupational, drug Kim, T., Taylor, J. S., Maibach, H. I., Chen, J. K., Honari, G. 2020

  Abstract

  BACKGROUND: Photopatch testing is an important diagnostic tool in evaluating patients with suspected photoallergic contact dermatitis. Although protocols for photopatch testing have been described, there are no consensus recommendations by the American Contact Dermatitis Society (ACDS).OBJECTIVES: The aims of this study were to examine the common practices of photopatch testing among ACDS members and to review and compare commonly used photoallergen series.METHODS: We conducted a questionnaire-based survey among ACDS members via e-mail to inquire about their photopatch test methods. We compared the results with the European consensus methodology and reviewed photoallergen series reported by the respondents.RESULTS: Of the 791 members contacted, 112 members (14%) responded to the survey. Among these, 50 respondents (45%) perform photopatch testing, approximately half of whom (48%) determine minimal erythema dose before the test using UVA with or without UVB irradiation. Respondents use a total of 13 photoallergen series, alone or in any combination, as well as customized series.CONCLUSIONS: These results have potential to aid clinicians in identifying photoallergen series best suited for their patients and suggest a need for consensus recommendations by the ACDS.

  View details for DOI 10.1097/DER.0000000000000535

  View details for PubMedID 31905187

• Dupilumab Treatment of Nummular Dermatitis: A Retrospective Cohort Study. Journal of the American Academy of Dermatology Choi, S. n., Zhu, G. A., Lewis, M. A., Honari, G. n., Chiou, A. S., Ko, J. n., Chen, J. K. 2020

  View details for DOI 10.1016/j.jaad.2019.12.054

  View details for PubMedID 31923445

• Dupilumab for occupational irritant hand dermatitis in a nonatopic individual: A case report. JAAD case reports Zhu, G. A., Honari, G. n., Ko, J. M., Chiou, A. S., Chen, J. K. 2020; 6 (4): 296–98

  View details for DOI 10.1016/j.jdcr.2020.02.010

  View details for PubMedID 32258302

  View details for PubMedCentralID PMC7109358

• Eczema, Targeted Therapeutics, and Allergy Diagnostics: The Need for Greater Clarity on What We Are Treating. Journal of the European Academy of Dermatology and Venereology : JEADV Chen, J. K., Honari, G. n., Silverberg, J. I. 2020

  Abstract

  Until recently, step-up therapy in atopic dermatitis (AD) included primarily off-label use of phototherapy, systemic immunosuppressants and/or corticosteroids. These broadly impact the immune system and show efficacy across a gamut of inflammatory skin diseases, albeit with potential serious adverse-events. Recently, dupilumab was approved as the first biologic agent in AD and demonstrated better efficacy and safety than prior off-label therapies.

  View details for DOI 10.1111/jdv.16445

  View details for PubMedID 32277506

• A PHASE 2, MULTI-Center, PLACEBO-CONTROLLED STUDY OF Single dose Squaric Acid Dibutyl Ester (sadbe) to reduce frequency of outbreaks IN SUBJECTS WITH RECURRENT HERPES LABIALIS. Journal of the American Academy of Dermatology Chang, A. L., Honari, G. n., Guan, L. n., Zhao, L. n., Palli, M. A., Horn, T. D., Dudek, A. Z., McTavish, H. n. 2020

  View details for DOI 10.1016/j.jaad.2020.04.021

  View details for PubMedID 32289388

• Facial Personal Protective Equipment: Materials, Resterilization Methods, and Management of Occupation-Related Dermatoses. Dermatitis : contact, atopic, occupational, drug Yu, J. n., Goldminz, A. n., Chisolm, S. n., Jacob, S. E., Zippin, J. H., Wu, P. A., Hylwa, S. n., Dunnick, C. A., Chen, J. K., Reeder, M. n., Honari, G. n., Atwater, A. R. 2020

  Abstract

  The coronavirus infectious disease 2019 pandemic has resulted in health care workers donning personal protective equipment (PPE) for extended periods.The aims of the study were to review facial PPE (surgical masks and N95 respirators) ingredients, to identify facial PPE resterilization techniques, and to recommend strategies for prevention and management of facial PPE-related dermatoses.Twenty-one facial PPE (11 N95 respirators, 10 surgical masks) were reviewed. Resterilization techniques were identified. Personal protective equipment-induced occupational dermatoses and management strategies were explored.Polypropylene is the most common chemical identified in facial PPE. Most masks contain aluminum at the nosepiece. Two surgical masks released nickel. Facial PPE dermatoses include irritant contact dermatitis, allergic contact dermatitis, acne, and contact urticaria. Strategies for prevention and management of facial PPE occupational dermatoses are discussed.There are increasing reports of occupational dermatoses associated with facial PPE. This review discusses the components of facial PPE, mask resterilization methods, and strategies for prevention and management of facial PPE dermatoses.

  View details for DOI 10.1097/DER.0000000000000699

  View details for PubMedID 33273243

• Inflammatory alopecia in patients on dupilumab: a retrospective cohort study at an academic institution. Journal of the European Academy of Dermatology and Venereology : JEADV Zhu, G. A., Kang, K. J., Chen, J. K., Novoa, R. A., Brown, R. A., Chiou, A. S., Ko, J. M., Honari, G. 2019

  Abstract

  Dupilumab targets IL-4Ralpha and is used for moderate-to-severe atopic dermatitis (AD). Prior reports have described new alopecia areata (AA),1 flaring of prior AA,2 as well as improvement or resolution of AA3 in patients treated with dupilumab. We conducted a retrospective cohort study to describe the natural history of prior or new inflammatory alopecia in patients on dupilumab.

  View details for DOI 10.1111/jdv.16094

  View details for PubMedID 31737955

• Pathophysiology and management of sensitive skin: position paper from the special interest group on sensitive skin of the International Forum for the Study of Itch (IFSI) JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY Misery, L., Weisshaar, E., Brenaut, E., Evers, A. M., Huet, F., Staender, S., Reich, A., Berardesca, E., Serra-Baldrich, E., Wallengren, J., Linder, D., Fluhr, J. W., Szepietowski, J. C., Maibach, H., Honari, G., Le Gall-Ianotto, C., Takamori, K., Richters, R., Int Forum Study Itch ISFI 2019

  Abstract

  The special interest group on sensitive skin of the International Forum for the Study of Itch previously defined sensitive skin as a syndrome defined by the occurrence of unpleasant sensations (stinging, burning, pain, pruritus and tingling sensations) in response to stimuli that normally should not provoke such sensations. This additional paper focuses on the pathophysiology and the management of sensitive skin. Sensitive skin is not an immunological disorder but is related to alterations of the skin nervous system. Skin barrier abnormalities are frequently associated, but there is no cause and direct relationship. Further studies are needed to better understand the pathophysiology of sensitive skin - as well as the inducing factors. Avoidance of possible triggering factors and the use of well-tolerated cosmetics, especially those containing inhibitors of unpleasant sensations, might be suggested for patients with sensitive skin. The role of psychosocial factors, such as stress or negative expectations, might be relevant for subgroups of patients. To date, there is no clinical trial supporting the use of topical or systemic drugs in sensitive skin. The published data are not sufficient to reach a consensus on sensitive skin management. In general, patients with sensitive skin require a personalized approach, taking into account various biomedical, neural and psychosocial factors affecting sensitive skin.

  View details for DOI 10.1111/jdv.16000

  View details for Web of Science ID 000492848800001

  View details for PubMedID 31660659

• Assessment of the Development of New Regional Dermatoses in Patients Treated for Atopic Dermatitis With Dupilumab JAMA DERMATOLOGY Zhu, G., Chen, J. K., Chiou, A., Ko, J., Honari, G. 2019; 155 (7): 850–52

  View details for DOI 10.1001/jamadermatol.2019.0109

  View details for Web of Science ID 000482127300017

• Repeat patch testing in a patient with allergic contact dermatitis improved on dupilumab. JAAD case reports Zhu, G. A., Chen, J. K., Chiou, A., Ko, J., Honari, G. 2019; 5 (4): 336–38

  View details for PubMedID 30989102

• Assessment of the Development of New Regional Dermatoses in Patients Treated for Atopic Dermatitis With Dupilumab. JAMA dermatology Zhu, G. A., Chen, J. K., Chiou, A. n., Ko, J. n., Honari, G. n. 2019

  View details for PubMedID 31042259

• Patch testing for nonimmediate cutaneous adverse drug reactions JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY Zinn, Z., Gayam, S., Chelliah, M. P., Honari, G., Teng, J. 2018; 78 (2): 421–23

  View details for PubMedID 29332717

• Defining Gaps in Dermatitis Care DERMATITIS Nedorost, S., Atwater, A., Ardern-Jones, M., Elias, P., Mukherjee, P., Honari, G., Ertel, M., Hammond, M., Machler, B., Scheman, A., Mulligan, K., Montanez-Wiskovich, M., Jacob, S., Brod, B. 2017; 28 (6): 372–74

  View details for DOI 10.1097/DER.0000000000000325

  View details for Web of Science ID 000415753100012

  View details for PubMedID 29135684

• Patch Testing for Evaluation of Hypersensitivity to Implanted Metal Devices: A Perspective From the American Contact Dermatitis Society DERMATITIS Schalock, P. C., Crawford, G., Nedorost, S., Scheinman, P. L., Atwater, A. R., Mowad, C., Brod, B., Ehrlich, A., Watsky, K. L., Sasseville, D., Silvestri, D., Worobec, S. M., Elliott, J. F., Honari, G., Powell, D. L., Taylor, J., DeKoven, J. 2016; 27 (5): 241-247

  Abstract

  The American Contact Dermatitis Society recognizes the interest in the evaluation and management of metal hypersensitivity reactions. Given the paucity of robust evidence with which to guide our practices, we provide reasonable evidence and expert opinion-based guidelines for clinicians with regard to metal hypersensitivity reaction testing and patient management. Routine preoperative evaluation in individuals with no history of adverse cutaneous reactions to metals or history of previous implant-related adverse events is not necessary. Patients with a clear self-reported history of metal reactions should be evaluated by patch testing before device implant. Patch testing is only 1 element in the assessment of causation in those with postimplantation morbidity. Metal exposure from the implanted device can cause sensitization, but a positive metal test does not prove symptom causality. The decision to replace an implanted device must include an assessment of all clinical factors and a thorough risk-benefit analysis by the treating physician(s) and patient.

  View details for DOI 10.1097/DER.0000000000000210

  View details for Web of Science ID 000384577700002

  View details for PubMedID 27649347